Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current trends in migraine prophylaxis.

Nabih M Ramadan1

  • 1Department of Neurology, Chicago Medical School at Rosalind Franklin University of Medicine and Science, North Chicago, IL 60064, USA.

Headache
|April 12, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ocular and Cervical Vestibular Evoked Myogenic Potentials in Patients With Vestibular Migraine.

Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology·2018
Same author

Glutamate and migraine: from Ikeda to the 21st century.

Cephalalgia : an international journal of headache·2013
Same author

Commentary on headache currents articles by Alhazzani and Goddeau.

Headache·2013
Same author

Reduced adverse event profile of orally inhaled DHE (MAP0004) vs IV DHE: potential mechanism.

Headache·2009
Same author

Safety and pharmacokinetics of dihydroergotamine mesylate administered via a Novel (Tempo) inhaler.

Headache·2008
Same author

The novel p.L1649Q mutation in the SCN1A epilepsy gene is associated with familial hemiplegic migraine: genetic and functional studies. Mutation in brief #957. Online.

Human mutation·2007
Same journal

Biochemical profiling and symptomatology of androgen deficiency in males with cluster headache: A prospective case-control study.

Headache·2026
Same journal

Thiamine deficiency in patients with chronic migraine: A case-control study.

Headache·2026
Same journal

Potential association of cluster headache with certain COVID-19 vaccines: An assessment from the pharmacovigilance databases.

Headache·2026
Same journal

Potential role of tirzepatide, a dual GLP-1 and GIP receptor agonist, for preventive treatment of migraine: A case series.

Headache·2026
Same journal

Adverse childhood experiences, migraine, and adverse pregnancy outcomes among teenage mothers.

Headache·2026
Same journal

Weight loss with atogepant in the long-term treatment of migraine: An interim analysis of a safety endpoint from a phase 3, multicenter, open-label, 156-week extension study.

Headache·2026
See all related articles

Migraine prevention drugs, including antidepressants and anticonvulsants, work by reducing neuronal excitability and restoring pain signaling. Balancing efficacy with side effects is key for optimal patient outcomes.

Area of Science:

  • Pharmacology
  • Neurology
  • Clinical Medicine

Background:

  • Migraine prevention historically relied on serendipitously discovered drugs from various classes.
  • Established preventive medications include beta-blockers, anticonvulsants, and tricyclic antidepressants.

Purpose of the Study:

  • To review current migraine preventive drugs and their mechanisms of action.
  • To discuss the evidence base for first-line migraine prophylaxis.
  • To highlight the importance of balancing drug efficacy with adverse effects.

Main Methods:

  • Review of pharmacological classes used in migraine prevention.
  • Analysis of proposed mechanisms targeting cortical excitation and nociceptive dysmodulation.
  • Evaluation of clinical evidence and expert opinion for first-line treatments.

Related Experiment Videos

Main Results:

  • Drugs like amitriptyline, divalproex, topiramate, propranolol, timolol, and metoprolol are favored first-line options.
  • Mechanisms involve inhibiting cortical spreading depression and modulating neurotransmitter systems.
  • Evidence for other drugs like verapamil is less robust.

Conclusions:

  • First-line migraine prevention relies on a select group of medications with established efficacy.
  • Balancing therapeutic benefits against adverse effects and patient factors is crucial.
  • Future drug development aims for more specific mechanisms to improve the therapeutic index.